Indications for Use:

Respisalph^® is intended for regular treatment of bronchial asthma when combination therapy with a long-acting beta2-adrenergic agonist and an inhaled glucocorticosteroid is indicated:

• For patients inadequately controlled on inhaled glucocorticosteroids alone with occasional use of short-acting beta2-adrenergic agonists
• For patients adequately controlled on inhaled glucocorticosteroids and a long-acting beta2-adrenergic agonist
• As initial maintenance therapy in patients with persistent bronchial asthma when indicated for simultaneous use of inhaled glucocorticoids and long-acting beta2-adrenergic agonists
• Respisalph^® is also intended for symptomatic treatment in chronic obstructive pulmonary disease (COPD) with a forced expiratory volume (FEV1) less than 60% of the predicted value (before bronchodilator use) and with a history of repeated exacerbations, where significant symptoms persist despite regular bronchodilator therapy.

Included in the List of Essential Medicines